Gene expression and neuronal activity in schizophrenia: A study of polyadenylated mRNA in the hippocampal formation and cerebral cortex

Schizophrenia Research

Volumn 26, Issue 2-3, 1997, Pages 93-102

  Harrison, Paul J ^a   Burnet, Philip W J ^a   Falkai, Peter ^b   Bogerts, Bernard ^c   Eastwood, Sharon L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BONN   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Hippocampus; Human brain; In situ hybridization; Messenger RNA; Neocortex; Parahippocampal gyrus

Indexed keywords

MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; POLYADENYLATED RNA; SULFUR 35;

ADULT; AGED; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; NERVE CELL; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; AGING; CEREBRAL CORTEX; FEMALE; FUNCTIONAL LATERALITY; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEURONS; RNA, MESSENGER; SCHIZOPHRENIA; TRANSCRIPTION, GENETIC;

EID: 0030796567     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(97)00048-0     Document Type: Article

References (54)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E. Jr., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry. 52:1995;258-266.
2. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E. Jr., Jones E.G. Selective alteration in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16:1996;19-30.
3. Arnold S.E., Franz B.R., Gur R.C., Gur R.E., Shapiro R.M., Moberg P.J., Trojanowski J.Q. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am. J. Psychiatry. 152:1995;738-748.
4. Arnold S.E., Hyman B.T., Van Hoesen G.W., Damasio A.R. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch. Gen. Psychiatry. 48:1991;625-632.
5. Arnold S.E., Trojanowski J.Q. Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathologica. 92:1996;217-231.
6. Barton A.J.L., Najlerahim A., Pearson R.C.A., Harrison P.J. Pre- and post mortem influences on brain RNA. J. Neurochem. 61:1993;1-11.
7. Bergeron C., Beric-Maskarel K., Muntasser S., Weyer L., Somerville M.J., Percy M.E. Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons. J. Neuropathol. Exp. Neurol. 53:1994;221-230.
8. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
9. Casanova M.F., Zito M., Altshuler L., Weinberger D.R., Kleinman J.E. Normal nucleolar size of entorhinal cortex cells in schizophrenia. Psychiatry Res. 44:1992;79-82.
10. Coleman P.D., Kazee A.M., Lapham L., Eskin T., Rogers K. Reduced GAP-43 message levels are associated with increased neurofibrillary tangle density in the frontal association cortex (area 9) in Alzheimer's disease. Neurobiol. Aging. 13:1992;631-639.
11. Doebler J.A., Markesbery W.R., Anthony A., Rhoads R.E. Neuronal RNA in relation to neuronal loss and neurofibrillary pathology in the hippocampus in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 46:1987;28-39.
12. Eastwood S.L., Burnet P.W., Harrison P.J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 66:1995;309-319.
13. Eastwood S.L., McDonald B., Burnet P.W.J., Beckwith J.P., Kerwin R.W., Harrison P.J. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29:1995;211-223.
14. Eastwood S.L., Burnet P.W.J., Harrison P.J. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Mol. Brain Res. 44:1997;92-98.
15. Falkai P., Bogerts B., Rozumek M. Limbic pathology in schizophrenia - the entorhinal region. Biol. Psychiatry. 24:1988;515-521.
16. Griffin W.S., Morrison M.R. In situ hybridization-visualization and quantitation of genetic expression in mammalian brain. Peptides. 6(Suppl. 2):1985;89-96.
17. Griffin W.S.T., Ling C., White C.L. III, Morrison-Bogorad M. Polyadenylated messenger RNA in paired helical filament-immunoreactive neurons in Alzheimer disease. Alz. Dis. Assoc. Disord. 4:1990;69-78.
18. Guillemette J.C., Wong L., Crapper-McLachlan D.R., Lewis P.N. Characterization of messenger RNA from the cerebral cortex of control and Alzheimer-afflicted brain. J. Neurochem. 47:1986;987-997.
19. Gur R.E., Mozley P.D., Resnick S.M., Mozley L.H., Shtasel D.L., Gallacher F., Arnold S.E., Karp J.S., Alavi A., Reivich M., Gur R.C. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch. Gen. Psychiatry. 52:1995;657-667.
20. Harrison, P.J., 1994. β Amyloid precursor protein gene expression and the pathogenesis of Alzheimer's disease. In: Weil, C., Muller, E.E., Thorner, M.O. (Series Eds.), Basic and Clinical Aspects of Neuroscience, vol. 6, Harrison, P.J. (Ed.), Regulation of Gene Expression and Brain Function. Springer-Verlag, Berlin, pp. 47-56.
21. Harrison P.J. Advances in post mortem molecular neurochemistry and neuropathology: examples from schizophrenia research. Br. Med. Bull. 52:1996;527-538.
22. Harrison, P.J., 1997. Schizophrenia and its dementia. In: Esiri, M.M., Morris, J.H. (Eds.), The Neuropathology of Dementia. Cambridge University Press, Cambridge, pp. 383-395.
23. Harrison P.J., Barton A.J.L., Najlerahim A., McDonald B., Pearson R.C.A. Regional and neuronal reductions of polyadenylated messenger RNA in Alzheimer's disease. Psychol. Med. 21:1991;855-866.
24. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
25. Harrison P.J., Heath P.R., Eastwood S.L., Burnet P.W.J., McDonald B., Pearson R.C.A. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 200:1995;151-154.
26. Harrison P.J., Procter A.W., Exworthy T., Roberts G.W., Najlerahim A., Barton A.J.L., Pearson R.C.A. Heat shock protein (hsx70) mRNA expression in human brain: effects of neurodegenerative disease and agonal state. Neuropathol. Appl. Neurobiol. 19:1993;10-21.
27. Harrison P.J., Eastwood S.L. Gene expression markers of neuronal activity and plasticity in the cerebral cortex in schizophrenia [abstract]. Schizophr. Res. 24:1997;86-87.
28. Hatanpää K., Brady D.R., Stoll J., Rapoport S.I., Chandrasekaran K. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 40:1996;411-420.
29. Huang Y.Q., Carmichael G.G. Role of polyadenylation in nucleocytoplasmic transport of mRNA. Mol. Cell. Biol. 16:1996;1534-1542.
30. Hyman B.T., Elvhage T.E., Reiter J. Extracellular signal regulated kinases: localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. Am. J. Pathol. 144:1994;565-572.
31. Jakob H., Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J. Neural Trans. 65:1986;303-326.
32. Johnson S.A., Morgan D.A., Finch C.E. Extensive postmortem stability of RNA from rat and human brain. J. Neurosci. Res. 16:1986;267-280.
33. Kingsbury A.E., Foster O.J.F., Nisbet A.P., Cairns N., Bray L., Eve D.J., Lees A.J., Marsden C.D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Mol. Brain Res. 28:1995;311-318.
34. Langstrom N.S., Anderson J.P., Lindroos H.G., Winblad B., Wallace W.C. Alzheimer's disease-associated reduction of polysomal mRNA translation. Mol. Brain Res. 5:1989;259-269.
35. Lustig R.H., Hua P., Wilson M.C., Federoff H.J. Ontogeny, sex dimorphism, and neonatal sex hormone determination of synapse-associated messenger RNAs in rat brain. Mol. Brain Res. 20:1993;101-110.
36. Mann D.M.A. Nerve cell protein metabolism and degenerative disease. Neuropathol. Appl. Neurobiol. 8:1982;161-176.
37. Mann D.M.A., Sinclair K.G.A. The quantitative assessment of lipofuscin pigment, cytoplasmic RNA and nucleolar volume in senile dementia. Neuropathol. Appl. Neurobiol. 4:1978;129-135.
38. Mutisya E.M., Bowling A.C., Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63:1994;2179-2184.
39. 1H MRS) of the hippocampal formation in schizophrenia: a pilot study. Br. J. Psychiatry. 165:1994;481-485.
40. Perlin J.B., Gerwin C.M., Panchison D.M., Vick R.S., Jakoi E.R., DeLorenzo R.J. Kindling produces long-lasting and selective changes in gene expression of hippocampal neurons. Proc. Natl. Acad. Sci. USA. 90:1993;1741-1745.
41. Perrett C.W., Marchbanks R.M., Whatley S.A. Characterisation of messenger RNA extracted post-mortem from the brains of schizophrenic, depressed and control subjects. J. Neurol. Neurosurg. Psychiatry. 51:1988;325-331.
42. Perrett C.W., Whatley S.A., Ferrier I.N., Marchbanks R.M. Changes in brain gene expression in schizophrenic and depressed patients. Schizophr. Res. 6:1992;193-200.
43. 2 receptor isoforms in brain tissue from controls and schizophrenics. Mol. Brain Res. 25:1994;173-175.
44. Roberts, G.W., 1991. Temporal lobe pathology and schizophrenia. In: Kerwin, R.W. (Ed.), Neurobiology and Psychiatry, vol. 1. Cambridge University Press, Cambridge, pp. 15-38.
45. Rockel A.J., Hiorns R.W., Powell T.P.S. The basic uniformity in structure of the neocortex. Brain. 103:1980;221-244.
46. Sachs A., Wahle E. Poly(A) tail metabolism and function in eucaryotes. J. Biol. Chem. 268:1993;22955-22958.
47. Salehi A., Ravid R., Gonatas N.N., Swaab D.F. Decreased activity of hippocampal neurons in Alzheimer's disease is not related to the presence of neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 54:1995;704-709.
48. 3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sci. USA. 90:1993;8942-8946.
49. Simonian N.A., Hyman B.T. Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J. Neuropathol. Exp. Neurol. 53:1994;508-512.
50. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., Carpenter W.T. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alteration with deficit syndrome. Arch. Gen. Psychiatry. 49:1992;522-530.
51. Torrey E.F., Johnston N.L., Cervenak J., Paltan J.D., Yolken R.H. Selecting postmortem brain tissue for research: how important is the postmortem interval? Schizophr. Res. 18:1996;182.
52. Virgo L., Humphries C., Mortimer A., Barnes T., Hirsch S., de Belleroche J. Cholecystokinin mRNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biol. Psychiatry. 37:1995;694-701.
53. Weinberger D.R., Berman K.F., Suddath R., Torrey E.F. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am. J. Psychiatry. 149:1992;890-897.
54. Zaidel D.W., Esiri M.M., Harrison P.J. The hippocampus in schizophrenia: lateralized increase in neuronal density and altered cytoarchitectural asymmetry. Psychol. Med. 27:1997;703-713.